Prolyl hydroxylase domain-containing proteins (PHDs) regulate the adaptation of cells to hypoxia. Pan-hydroxylase inhibition is protective in experimental colitis, in which PHD1 plays a prominent role. However, it is currently unknown how PHD1 targeting regulates this protection and which cell type(s) are involved. Here, we demonstrated that Phd1 deletion in endothelial and haematopoietic cells (Phd1 f/f Tie2:cre) protected mice from dextran sulphate sodium (DSS)-induced colitis, with reduced epithelial erosions, immune cell infiltration, and colonic microvascular dysfunction, whereas the response of Phd2 f/+ Tie2:cre and Phd3 f/f Tie2:cre mice to DSS was similar to that of their littermate controls. Using bone marrow chimeras and cell-specific cre mice, we demonstrated that ablation of Phd1 in haematopoietic cells but not in endothelial cells was both necessary and sufficient to inhibit experimental colitis. This effect relied, at least in part, on skewing of Phd1-deficient bone marrow-derived macrophages towards an anti-inflammatory M2 phenotype. These cells showed an attenuated nuclear factor-B-dependent response to lipopolysaccharide (LPS), which in turn diminished endothelial chemokine expression. In addition, Phd1 deficiency in dendritic cells significantly reduced interleukin-1 production in response to LPS. Taken together, our results further support the development of selective PHD1 inhibitors for ulcerative colitis, and identify haematopoietic cells as their primary target.
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prolyl hydroxylase domain-containing proteins (PHDs). Under normoxic conditions, these enzymes induce the ubiquitination of the hypoxia-inducible factor (HIF) subunits HIF-1α and HIF-2α, which leads to their proteasomal degradation. During hypoxia, the enzymatic activity of PHDs is inhibited, which ensures the stabilization of HIFα subunits and the formation of the active transcription factors HIF-1 and HIF-2. These effects, in turn, transactivate the expression of genes involved in angiogenesis, erythropoiesis, cell migration, and metabolism, thereby protecting the host cell against low oxygen conditions [1, 2] .
PHDs have been investigated as therapeutic targets in IBD. In particular, pan-hydroxylase inhibitors ameliorate disease in murine IBD models and are set to enter the clinical trial phase [3] [4] [5] . However, potential risks, including the promotion of tumour growth through increasing angiogenic potential, and cardiovascular events, may be associated with systemic pan-hydroxylase inhibition [6] [7] [8] . Therefore, current research is focusing on the role of the different PHD isoforms (PHD1-PHD3) in the pathogenesis of IBD. We have recently demonstrated that PHD1 expression is increased in inflamed IBD biopsies, especially in active UC [9] . Consistent with these findings, Tambuwala et al demonstrated that Phd1-deficient mice are protected against colitis [10] . However, it is unknown which cell type(s) need to be targeted to achieve these beneficial effects. It was hypothesized that epithelial PHD1 mediated this protection by decreasing epithelial cell apoptosis and barrier dysfunction, both of which are prominent features of active IBD. However, this might be a secondary phenomenon, because the epithelial apoptosis rate seems to be driven by the local inflammatory response rather than vice versa [11] . This is supported by the fact that the currently available effective therapeutic strategies in IBD intervene at the site of the immune cells [corticosteroids, purine analogues, methotrexate, cyclosporine, anti-tumour necrosis factor (TNF)-α), anti-interleukin (IL)-12/IL-23] or in the interaction of these immune cells with the intestinal microvessels (anti-integrins and anti-mucosal vascular addressin cell adhesion molecule 1) [12, 13] . We therefore investigated the role of PHD1-PHD3 in endothelial and haematopoietic cells in blood vessel function, epithelial integrity and the inflammatory burden in experimental colitis.
Materials and methods

Animals
The mice used in this study were male and females on a C57BL/6 background. The generation of the floxed Phd1 f/f , Phd2 f/f and Phd3 f/f mice has been described previously [14] [15] [16] [18] [19] [20] . Mice from different genotypes were cage-mixed during each experiment to minimize the influence of gut microbiota [21] .
The mice were bred and housed in individually ventilated cages in a temperature-controlled room at 22 ∘ C with a 12-h/12-h light/dark cycle. The mice had free access to water and commercial chow (mice maintenance chow; Carfil Labofood, Pavan Service, Belgium). All mice were treated in accordance with the institutional animal health care guidelines, following study approval (ECD2010/40, ECD2013/49, ECD2015/21, ECD2015/58, and ECD2016/29) by the Institutional Review Board at the Faculty of Medicine and Health Sciences of Ghent University.
Induction of colitis and bone marrow (BM) transplantation
Eight-to-twelve-week-old Phd1 f/f Tie2:cre, Phd2
Tie2:cre and Phd3 f/f Tie2:cre mice and their corresponding wild-type (WT) littermate control mice, i.e.
Phd1
f/f , Phd2 f/+ , and Phd3 f/f , respectively, received 4% dextran sulphate sodium (DSS) (molecular mass of 36 000-50 000; MP Biomedicals, Santa Ana, CA, USA) in their drinking water for seven consecutive days, followed by normal drinking water. Phd1 f/f Flk-1:cre mice, Phd1 f/f Vav:cre mice and their corresponding WT littermate mice were given 3% DSS. Uptake of DSS-containing water was monitored daily, and was comparable between cages. Over time, the DSS dosage had to be adjusted to 3%, because 4% DSS led to more severe induction of colitis with a high mortality rate, probably because of the environmental and structural changes in our animal facility. The disease activity index (DAI) was determined according to the criteria proposed by Cooper et al [22] .
One week prior to irradiation, the mice for BM transplantation received acidified water (pH between 2.4 and 3.1) that contained 0.1 mg/ml neomycin (Sigma-Aldrich, Diegem, Belgium) and 0.01 mg/ml polymyxin B sulphate (Sigma-Aldrich). Six-to-eightweek-old mice were subjected to 9.5-Gy lethal total-body irradiation with an X-ray source. Between 4 and 12 h later, the mice were intravenously reconstituted with BM cells (10 7 ) prepared from the femur, tibia and humeri of WT or Phd1 f/f Tie2:cre mice. Following irradiation and BM transplantation, the mice were maintained on acidified, antibiotic-containing water, and were allowed to recover for 8 weeks on a chow diet.
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Dynamic contrast-enhanced magnetic resonance (MR) imaging (DCE-MRI) for vascular permeability measurements during colitis
The MR images were acquired on a 7-T small-animal system (BioSpin Pharmascan 70/16; Bruker, Ettlingen, Germany) with a mouse body volume coil. The mice were anaesthetized with isoflurane (5% induction and 1.5% maintenance, mixed with medical oxygen) and actively heated with a water-based heating blanket. Anatomical information was obtained with a T1-weighted sequence (rapid imaging with refocused echoes) with the following parameters: repetition time (TR) of 1453 ms; echo time (TE) of 9. A two-compartment model (blood and extracellular extravascular space) was used to obtain parametric maps with K trans values on a pixel-by-pixel basis [23] . These K trans values constitute a measure of the vascular leakage, and the mean K trans values were calculated for each colonic slice of each mouse.
Isolation and culture of BM-derived macrophages (BMDMs) and BM-derived dendritic cells (BMDCs)
Primary BMDMs and BMDCs were isolated by flushing the BM out of the femur and tibia. BMDMs were subsequently cultured in 10 × 15-mm Petri dishes in Dulbecco's modified Eagle's medium + glutamax supplemented with 10% fetal bovine serum (Invitrogen, Ghent, Belgium), penicillin/streptomycin (Invitrogen), and 20 ng/ml recombinant murine macrophage colony-stimulating factor (Peprotech, London, UK) with a complete change of medium every 2-3 days. BMDC cultures were set up according to the protocol originally published by Lutz et al [24] . After 5 days, 10 6 BMDMs were stimulated for 24 h with 100 ng/ml lipopolysaccharide (LPS) (Ultrapure LPS from Escherichia coli K; Invivogen, San Diego, CA, USA), 20 ng/ml murine recombinant IL-4 (Peprotech), 125 nM ACHP (Tocris, Bristol, UK) and 20 ng/ml IL-4 or an equal volume of placebo. After 10 days in culture, 10 6 BMDCs were treated for 16 h with 100 ng/ml LPS (Invitrogen) or an equal volume of placebo. The cells were subsequently lysed for RNA isolation, and the supernatant was collected.
Statistical analysis
Data were analysed with SPSS Statistics, version 22, for Windows (SPSS, Chicago, IL, USA) or GraphPad Prism software (GraphPad Software, San Diego, CA, USA). In the case of normally distributed data, the differences between the groups were analysed with an unpaired Student's t-test for independent samples. For the non-normal or unknown data distributions, the groups were compared by use of the non-parametric Mann-Whitney U-test. Continuous data (body weight and DAI changes) were analysed with linear mixed models. Two-tailed probabilities were calculated, and a p-value of <0.05 was considered to be statistically significant.
Results
Characterization of Phd1 f/f Tie2:cre mice
To determine the degree of Phd1 recombination in cre mice, quantitative PCR primers were designed to detect the Phd1 allele as it occurs in WT mice, whereas the other primers bind the remaining Phd1 allele as it occurs following recombination in Phd1 f/f Tie2:cre mice. In WT mice, the forward primer binds the Phd1 cDNA sequence at exon 2, before the floxed exons (exon 3 and exon 4), whereas the reverse primer binds exon 3, which will be deleted if recombination occurs (supplementary material, Figure S1F , left). As a positive control for effective recombination, the following primers were designed: one that binds at the transition between exon 2 and exon 5, which does not occur in WT mice, and a reverse primer that binds exon 5 (supplementary material, Figure S1F , right). Thus, the allele detected by the first primer pair will be referred to hereafter as 'Phd1 wt', whereas the 'remaining' Phd1 allele, detected by the second primer pair, will be referred to as 'Phd1 ko'. The primer sequences are provided in supplementary material, Table S1 . It has been reported that, when crossed with floxed mice, Tie2:cre mice generate recombination of the floxed gene in endothelial and haematopoietic cells [17] . We therefore first examined whether efficient recombination occurs in these cellular compartments of our mice. To this end, we isolated BM and colonic endothelial cells from Phd1 f/f Tie2:cre and WT mice. BM, BMDMs and BMDCs showed decreases in Phd1 mRNA of 62%, 85% and 85%, respectively (supplementary material, Figure S1A -C), and a concomitant increase in Phd1 ko expression. Additionally, CD4
+ T lymphocytes isolated from the spleen showed a 75% reduction in the Phd1 mRNA level accompanied by increased Phd1 ko expression (supplementary material, Figure S1D ). In addition, we isolated colonic epithelial cells from Phd1 f/f Tie2:cre and WT mice as a negative control, as well as to confirm potential effects 550 S Van Welden et al arising exclusively from endothelial or haematopoietic knockout. As expected, the colonic epithelial cells from both Phd1 f/f Tie2:cre and WT mice showed comparable Phd1 mRNA levels. Consistent with this finding, no expression of the Phd1 ko allele was identified in the groups (supplementary material, Figure S1E ). However, Phd1 mRNA expression in the isolated primary colonic endothelial cells was decreased by only 37%, with slight induction of Phd1 ko expression (supplementary material, Figure S1F , left). As a consequence, we concluded that Tie2:cre transgenic mice do not constitute the best model with which to generate efficient knockdown in the colonic vasculature. Therefore, the effect of endothelial-specific Phd1 knockdown was re-evaluated with Phd1 f/f Flk-1:cre mice, for which Phd1 mRNA expression in isolated primary colonic endothelial cells was reduced by 75% and a concomitant increase in Phd1 ko expression was observed (supplementary material, Figure S1F , right).
Phd1 f/f Tie2:cre mice show highly attenuated signs of inflammation and blood vessel dysfunction during DSS-induced colitis
We generated Phd1 f/f Tie2:cre, Phd2 f/+ Tie2:cre and Phd3 f/f Tie2:cre mice that are conditionally deficient for Phd1, Phd2 and Phd3, respectively, in both endothelial and haematopoietic cells. To investigate the effect of conditional Phd1-Phd3 deficiency on colitogenesis, we subjected these mice and their respective WT littermate controls to DSS-induced colitis, and compared their clinical parameters. Phd1 f/f Tie2:cre mice but not Phd2 f/+ Tie2:cre or Phd3 f/f Tie2:cre mice were significantly protected from DSS-induced colitis as determined by weight loss, DAI, colonic shortening and histological inflammation score ( Figure 1A -E) as compared with WT mice. In addition, we observed fewer epithelial erosions and less infiltration of inflammatory cells in Phd1 f/f Tie2:cre mice ( Figure 1F, G) . In contrast, weight evolution and histological inflammation score were not attenuated in the colitic Phd2 f/+ Tie2:cre and Phd3 f/f Tie2:cre mice as compared with their respective littermate controls ( Figure 1A-C) . We subsequently questioned whether Phd1 deficiency influenced colonic blood vessel function. We therefore evaluated the in vivo colonic microvascular leakage at days 0, 3 and 7 during the course of colitis, by using DCE-MRI (Figure 2A , B). At day 3, no change in leakage was identified as compared with day 0. However, vascular leakage in WT mice was significantly increased at day 7, whereas Phd1 f/f Tie2:cre mice showed leakage comparable to the baseline levels. Consistent with these findings, at the end of the DSS experiment (day 11), the mRNA expression levels of the known endothelial dysfunction markers Icam1, Vcam1, Madcam1, Vwf and Vegfr2 were strongly increased at the end of the DSS experiment (day 11) in WT mice, whereas the expression levels of these markers were significantly lower in the Phd1 f/f Tie2:cre littermates ( Figure 2C ). In addition, the expression levels of these endothelial dysfunction markers in Phd2 f/+ Tie2:cre and Phd3 f/f Tie2:cre mice were comparable with those of their corresponding littermate controls (data not shown). Collectively, these findings demonstrate that Phd1 f/f Tie2:cre mice are selectively protected against the development of colitis and its associated endothelial dysfunction.
Endothelial Phd1 deficiency alone does not rescue mice from DSS-induced colitis Next, we questioned whether the strong protective effects identified in Phd1 f/f Tie2:cre mice resulted exclusively from Phd1 targeting in endothelial cells. We therefore irradiated Phd1 f/f Tie2:cre mice and their littermate WT controls, and intravenously injected them with WT BM to generate WT < -WT BM chimeras and Phd1 f/f Tie2:cre < -WT BM chimeras. Unexpectedly, no amelioration in terms of body weight, colon length or histological inflammation was identified in Phd1 f/f Tie2:cre < -WT BM chimeras ( Figure 3A -C, left). Phd1 f/f Tie2:cre mice showed only a slight reduction in Phd1 mRNA expression in colonic endothelial cells, as mentioned earlier; thus, we re-evaluated the effect of endothelial Phd1 deficiency on colitogenesis by using Flk-1:cre mice, which generate effective and specific recombination in endothelial cells (supplementary material, Figure S1F , right). However, Phd1 f/f Flk-1:cre mice were also not protected from DSS-induced colitis ( Figure 3A-C, right) . These findings conclusively demonstrate that endothelial cells are not the primary targets for Phd1 deletion to protect mice from DSS-induced colitis.
Haematopoietic Phd1 deficiency is essential to confer protection against DSS-induced colitis As Phd1 f/f Tie2:cre mice also show knockdown of Phd1 in different cell types from the haematopoietic compartment, we questioned whether selective Phd1 deletion in these cells may render mice less susceptible to colitogenesis. We therefore irradiated WT mice, and half of the mice received WT BM from their WT littermate controls, which resulted in WT < -WT BM chimeras. The remaining irradiated WT mice were injected with BM from their littermate Phd1 f/f Tie2:cre mice to generate WT < -Phd1 f/f Tie2:cre BM chimeras, which show sole knockout of Phd1 in all haematopoietic cells. Eight weeks after irradiation, the mice were subjected to 3% DSS. Strikingly, WT < -Phd1 f/f Tie2:cre BM chimeras were significantly protected from DSS-induced colitis, which was shown by reduced weight loss, colon shortening and histological inflammation score as compared with WT < -WT BM chimeras (Figure 4A-D) . Also, fewer epithelial erosions and less infiltration of inflammatory cells were observed ( Figure 4E, F) . In addition, the levels of Icam1, Vcam1, Vwf and Vegfr2 mRNAs were significantly reduced in WT < -Phd1 f/f Tie2:cre These mice showed significantly improved body weight evolution as compared with their WT littermate controls ( Figure 4H ). Collectively, these findings demonstrate that loss of Phd1 in haematopoietic cells is both necessary and sufficient to reduce mucosal inflammation and its associated endothelial dysfunction during colitis.
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Loss of Phd1 in BMDMs promotes their skewing towards an M2 phenotype with reduced response to LPS
We subsequently questioned which cell type(s) within this haematopoietic pool is (are) the main contributor(s) to these protective effects. We first focused on macrophages, because they are key players in both the onset and resolution of inflammation in DSS-induced colitis, depending on their phenotype [25] [26] [27] . Whereas M1 macrophages secrete pro-inflammatory cytokines, M2 macrophages secrete anti-inflammatory cytokines, and growth and angiogenic factors responsible for vascular remodelling and tissue repair. We found that Phd1 f/f Tie2:cre BMDMs showed increased expression of the M2 marker Arg1 at baseline as compared with WT BMDMs. Moreover, when M2 conversion was induced with IL-4, increased mRNA levels of the M2 markers Chi3l3, Fizz1 and Arg1 were seen in the Phd1 f/f Tie2:cre BMDMs as compared with WT BMDMs (Figure 5A ).
To assess the anti-inflammatory nature of these Phd1-deficient macrophages, we stimulated BMDMs from both WT and Phd1 f/f Tie2:cre mice with LPS, and determined the secretion of pro-inflammatory cytokines and chemokines. The supernatant from Phd1 f/f Tie2:cre BMDMs contained significantly lower levels of IL-1β, IL-6, TNF-α and MCP-1 than the supernatant from WT BMDMs ( Figure 5B ). In addition, when this supernatant was added to MS1 endothelial cells, induction of the endothelial chemokines Cxcl2 and Mcp1 was significantly suppressed as compared with endothelial cells stimulated with LPS conditioned medium from WT BMDMs (supplementary material, Figure S2 ).
Taken together, these observations indicate that loss of Phd1 skews macrophages towards an M2 phenotype with a reduced inflammatory response to LPS.
The nuclear factor-κB (NF-κB) activation state is altered during steady-state and inflammatory conditions upon loss of Phd1 in BMDMs, and is partly responsible for the promotion of M2 conversion As TNF-α, IL-6, IL-1β and MCP-1 expression can all be regulated by NF-κB, and the latter can also be upregulated by pan-hydroxylase inhibition [28] , we determined the impact of Phd1 deletion in macrophages on the expression of signal transducers in the NF-κB pathway in steady-state and inflammatory conditions. At baseline, Phd1 f/f Tie2:cre BMDMs showed increased levels of phosphorylated IκBα (P-IκBα) and phosphorylated p65 (P-p65) as compared with WT BMDMs (Figure 6A, B) . Accordingly, the expression of IκBα, a known NF-κB target [29] , was significantly increased in Phd1 f/f Tie2:cre BMDMs as compared with WT BMDMs ( Figure 6B ). We next questioned whether the increased NF-κB activity at baseline in Phd1 f/f Tie2:cre BMDMs was responsible for the facilitation of M2 polarization. We therefore incubated WT and Phd1 f/f Tie2:cre BMDMs with IL-4 or with the NF-κB inhibitor ACHP, which is, in fact, an IκB kinase inhibitor, or with ACHP in combination with IL-4. We observed that inhibition of NF-κB in Phd1 f/f Tie2:cre BMDMs reduced the IL-4-induced increase in Chi3l3 and Fizz1 expression to levels comparable with those in ACHP-treated and IL-4-treated WT BMDMs ( Figure 6C ). The expression of Arg1 
remained elevated in ACHP-treated and IL-4-treated
Phd1
f/f Tie2:cre BMDMs, indicating that NF-κB is not involved in the regulation of this M2 marker ( Figure 6C ). Taken together, these findings indicate that the increased baseline NF-κB activity in Phd1 f/f Tie2:cre BMDMs is partly responsible for their facilitated M2 conversion.
However, after LPS stimulation, P-IκBα levels were significantly less increased in Phd1 f/f Tie2:cre BMDMs than in WT BMDMs ( Figure 6A ), which indicates LPS tolerance in Phd1 f/f Tie2:cre BMDMs that could account for the reduced levels of the aforementioned inflammatory cytokines and chemokine.
Loss of Phd1 in BMDCs reduces LPS-induced IL-1β secretion
In addition to macrophages, dendritic cells (DCs) are also essential in the maintenance of tissue homeostasis in the intestinal microenvironment through the induction of tolerance [30] . Pathological disorders such as IBD alter the DC phenotype, inducing a more pro-inflammatory state, and infusion of these inflammatory DCs is sufficient to induce and propagate inflammation [31] . Therefore, we investigated whether Phd1-deficient DCs could also play a role in the protection seen after haematopoietic Phd1 knockout. We therefore set up BMDC cultures from WT and Phd1 f/f CD11c:cre mice. The CD11c-driven expression of the Cre recombinase transgene efficiently abolished Phd1 expression in BMDCs (data not shown). The resulting BMDCs were stimulated with LPS, and the levels of secreted cytokines were determined. DCs from Phd1 f/f CD11c:cre mice secreted significantly lower amounts of IL-1β, and there was a trend towards 
Phd1 deficiency does not influence T-cell cytokine secretion after activation
In addition to beneficial effects on members of the innate immune system (BMDMs and BMDCs), we wanted to know whether Phd1 knockout also influenced T-cell functioning, because CD4 + T cells are known to play an important role in the course of DSS-induced colitis [32, 33] . Hence, we stimulated spleen single-cell suspensions from WT and Phd1 f/f Vav:cre mice with phorbol 12-myristate 13-acetate and ionomycin to specifically accomplish T-cell activation, and, 4 h later, determined cytokine levels in the supernatant. First, we analysed the degree of Phd1 knockout in CD4 + T-cells. As expected, CD4 + T cells from Phd1 f/f Vav:cre mice showed complete deletion of Phd1, in contrast to the expression in WT CD4
+ T cells (data not shown). When we compared the levels of interferon-γ, TNF-α, and IL-10, no significant differences could be detected between WT and Phd1 f/f Vav:cre mice (supplementary material, Figure  S3 ). These results suggest that Phd1 deletion does not affect T-cell cytokine release. dysfunction in mice. We revealed that these beneficial effects are, at least in part, mediated by promotion of Phd1-deficient macrophages towards M2 polarization, with a diminished pro-inflammatory response to LPS.
In line with the previously reported results of Tambuwala et al [10] , we observed that Phd1, and not Phd2 or Phd3, needs to be targeted in order to achieve protection from DSS-induced colitis. However, whereas Tambuwala et al proposed a reduction in colonic epithelial apoptosis with resulting preservation of barrier function as a primary mechanism, we showed that genetic deletion in endothelial and haematopoietic cells was sufficient to elicit strong protection against DSS-induced colitis, with less epithelial erosion, preservation of mucosal microvascular barrier function, and lower expression levels of the endothelial dysfunction markers Icam1, Vcam1, Madcam1, Vwf , and Vegfr2.
We endeavoured to identify the key cell types and mechanisms behind this strong protective effect, by focusing on the main cell types involved in colitogenesis. By using BM chimeras and cell-specific cre mice, we were able to show that deletion of Phd1 in haematopoietic but not endothelial cells was critical to confer protection from colitis. Interestingly, whereas Phd1 deletion in activated T cells did not alter their cytokine secretion, and that PHD1 in neutrophils does not seem to play a role during hypoxic and inflammatory conditions, based on previous observations [10, 34] , we identified an important role for Phd1 within the mononuclear phagocyte system. We demonstrated that Phd1 deletion in BMDMs was accompanied by facilitation of M2 polarization. Consistent with this finding, Hams et al showed that administration of dimethyloxalylglycine (DMOG), a pan-hydroxylase inhibitor, is also associated with enhanced levels of M2 markers [35] , which suggests that inhibition of PHD1 might be involved in this effect. In addition, the M2 phenotype caused by Phd1 deletion was accompanied by significantly lower amounts of the pro-inflammatory cytokines IL-1β, IL-6 and TNF-α and the chemokine MCP-1 following stimulation with LPS. This phenotypic switch could be particularly relevant in IBD, in which, on the one hand, the intestinal mucosa is characterized by an increased proportion of M1 macrophages [36] that directly contribute to epithelial barrier disruption, mainly through TNF-α release [37] , and, on the other hand, by a decreased proportion of pro-angiogenic 'wound-healing' M2 macrophages [38, 39] . This imbalance is also present in DSS-induced colitis, and the disease course can be ameliorated by adoptive transfer of M2 macrophages [26] . Also, proteins and metabolites that promote M2 conversion are effective in reducing the severity of experimental colitis [40] [41] [42] .
To further dissect the molecular mechanism by which Phd1 deletion in BMDMs altered their phenotype, we focused on NF-κB, as its activation can be regulated by PHDs [43] , and it is a key transcriptional regulator of both M1 and M2 polarization [44] . We found increased levels of P-IκBα and P-p65 and elevated expression of the NF-κB target IκBα in Phd1-deficient BMDMs as compared with WT BMDMs, which is in line with previous observations showing induction of NF-κB activity upon knockdown of PHD1 in HeLa cells [28] . Moreover, we demonstrated that this elevated baseline NF-κB activity in Phd1-deficient BMDMs is partly responsible for the facilitation of M2 polarization. On the other hand, P-IκBα levels after LPS administration were markedly lower in Phd1 f/f Tie2:cre BMDMs than in WT BMDMs. This indicates that, despite the higher baseline NF-κB activation, Phd1 f/f Tie2:cre BMDMs are less responsive to an inflammatory stimulus, which explained their reduced LPS-induced secretion of IL-1β, IL-6, TNF-α and MCP-1 in Phd1 f/f Tie2:cre BMDMs as compared with WT BMDMs. A similar apparent paradox has been found with the use of DMOG. In addition to increasing HIF-1α levels, DMOG moderately increases basal NF-κB activity [28, 35] , which renders cells tolerant to subsequent NF-κB activation induced by LPS, and, as a result, limited further NF-κB activation is observed with subsequent diminished NF-κBproteins associated with the TRAF6 complex [46] . As the latter is also a major component of the LPS pathway, this could explain how Phd1 deletion induces LPS tolerance.
Furthermore, we demonstrated that the supernatant from LPS-stimulated Phd1-deficient macrophages was able to partly diminish the pro-inflammatory signature of endothelial cells, which suggests that Phd1 deficiency in BMDMs could be responsible, at least in part, for the attenuation of colitis-associated endothelial dysfunction and leukocyte trafficking. In addition to macrophages, we investigated the effect of genetic Phd1 deletion in DCs, and showed, for the first time, that Phd1-deficient DCs show a marked decrease in IL-1β release in response to LPS. IL-1β is a pro-inflammatory cytokine whose level is elevated in active IBD [47] and has been shown to alter tight junction protein expression and distribution, which consequently disrupt epithelial barrier integrity [48] . Therefore, Phd1-deficient macrophages and DCs may work synergistically in preserving barrier function during colitis through the reduced release of IL-1β. Thus, Phd1 deficiency in mononuclear phagocytes, in addition to epithelial cells, regulates epithelial barrier integrity.
Future studies will have to address the translatability of our findings to human IBD. To date, no PHD1-specific inhibitor exists. However, one company (Aerpio Therapeutics) is currently developing a non-selective PHD inhibitor for clinical use in IBD.
In conclusion, we have demonstrated, for the first time, that PHD1 exerts critical functions in haematopoietic cells, more specifically in the mononuclear phagocyte system, that drive experimental colitis. Our results further support the development of PHD1-specific inhibitors for the treatment of UC.
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